Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

2025 ISPE European Annual Conference

The 2025 ISPE European Annual Conference will gather pharmaceutical and biopharmaceutical professionals from across the industry — from students and emerging talent to senior executives [...]

Go to Top